Exenatide Use in the Management of Type 2 Diabetes Mellitus
Exenatide is a GLP-1 (glucagon-like peptide-1) agonist that has been approved in the UK for use in the management of Type 2 Diabetes Mellitus (T2DM) since 2006. It acts by increasing glucose-induced insulin release and by reducing glucagon secretion postprandially. It therefore increases insulin sec...
| Κύριοι συγγραφείς: | , |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | English |
| Έκδοση: |
MDPI AG
2010-08-01
|
| Σειρά: | Pharmaceuticals |
| Θέματα: | |
| Διαθέσιμο Online: | http://www.mdpi.com/1424-8247/3/8/2554/ |